BioSpace News Archive

Retia Medical, LLC announced today that three of the top five U.S. hospitals completed a purchase of a large number of Argos Hemodynamic Monitors.

Ranbaxy Pharmaceuticals Canada Inc. is recalling all lots of its prescription ranitidine products from the Canadian market as a precautionary measure.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the appointment of seasoned life sciences executive Peter Soparkar as chief legal officer.

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company will release its financial results for the third quarter of 2019 after the market closes on Wednesday, November 6, 2019.

PRA Health Sciences, Inc. reported financial results for the quarter ended September 30, 2019.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal first-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Monday, November 4, 2019.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that its third quarter 2019 financial results will be reported on Wednesday, November 6, 2019 after the close of the financial markets.

Rhythm Pharmaceuticals, Inc. announced that it will present clinical data from its two pivotal Phase 3 clinical trials evaluating setmelanotide for the treatment of pro-opiomelanocortin and leptin receptor deficiency obesities, as well as preclinical data characterizing missense variants within the melanocortin-4 receptor pathway, during the 37th Annual Meeting of The Obesity Society at ObesityWeek® 2019, Nov. 3-7, at Mandalay Bay South Convention Center in Las Vegas.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that its third quarter 2019 operational progress and financial results will be released before the market opens on Thursday, November 7, 2019.

Merit Medical Systems, Inc. announced revenue of $243.0 million for the quarter ended September 30, 2019, an increase of 9.6% over revenue of $221.7 million for the quarter ended September 30, 2018.